Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19.
Male
Humans
Middle Aged
Positron Emission Tomography Computed Tomography
Retrospective Studies
COVID-19
/ complications
Brain
/ diagnostic imaging
Positron-Emission Tomography
/ methods
Fluorodeoxyglucose F18
/ metabolism
Cognition
Alzheimer Disease
/ metabolism
Cognitive Dysfunction
/ diagnostic imaging
18F-amyloid PET/CT
COVID-19
Cognitive function
Hypometabolism
Long COVID
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
05
09
2022
accepted:
20
12
2022
revised:
19
12
2022
pubmed:
25
1
2023
medline:
22
3
2023
entrez:
24
1
2023
Statut:
ppublish
Résumé
Emerging evidence indicates that the etiologic agent responsible for coronavirus disease 2019 (COVID-19), can cause neurological complications. COVID-19 may induce cognitive impairment through multiple mechanisms. The aim of the present study was to describe the possible neuropsychological and metabolic neuroimaging consequences of COVID-19 12 months after patients' hospital discharge. We retrospectively recruited 7 patients (age [mean ± SD] = 56 years ± 12.39, 4 men) who had been hospitalized for COVID-19 with persistent neuropsychological deficits 12 months after hospital discharge. All patients underwent cognitive assessment and brain (
Identifiants
pubmed: 36692636
doi: 10.1007/s00415-022-11543-8
pii: 10.1007/s00415-022-11543-8
pmc: PMC9873215
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1823-1834Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Priori A, Senior E, Dini M, Deputy E (2021) Neurology of COVID-19. Milano university press, Milan
doi: 10.54103/milanoup.57
Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H et al (2021) 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging 48:2823–33
doi: 10.1007/s00259-021-05215-4
pubmed: 33501506
pmcid: 7837643
Kas A, Soret M, Pyatigoskaya N, Habert M-O, Hesters A, Le Guennec L et al (2021) The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur J Nucl Med Mol Imaging. 48:2543–57
doi: 10.1007/s00259-020-05178-y
pubmed: 33452633
pmcid: 7810428
Miskowiak KW, Johnsen S, Sattler SM, Nielsen S, Kunalan K, Rungby J et al (2021) Cognitive impairments four months after COVID-19 hospital discharge: pattern, severity and association with illness variables. Eur Neuropsychopharmacol Elsevier B.V. 46:39–48
doi: 10.1016/j.euroneuro.2021.03.019
Baker HA, Safavynia SA, Evered LA (2021) The ‘third wave’: impending cognitive and functional decline in COVID-19 survivors. Br J Anaesth 126:44–47
doi: 10.1016/j.bja.2020.09.045
pubmed: 33187638
Vijiala S, Epiney J-B, Jöhr J, Pincherle A, Meyer MM, Du Pasquier R, et al (2021) Case report: behavioral unresponsiveness in acute COVID-19 patients: the utility of the motor behavior tool-revised and (18)F-FDG PET/CT. Front Neurol 644848
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet Elsevier Ltd 395:507–513
doi: 10.1016/S0140-6736(20)30211-7
Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kuruvilla DE, Spudich S (2020) Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 77:1018–1027
doi: 10.1001/jamaneurol.2020.2065
pubmed: 32469387
pmcid: 7484225
Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, et al (2021) Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med 218(3):e20202135. https://doi.org/10.1084/jem.20202135
doi: 10.1084/jem.20202135
pubmed: 33433624
pmcid: 7808299
Safavynia SA, Goldstein PA (2019) The role of neuroinflammation in postoperative cognitive dysfunction: moving from hypothesis to treatment. Front Psychiatry 9:752. https://doi.org/10.3389/fpsyt.2018.00752
doi: 10.3389/fpsyt.2018.00752
pubmed: 30705643
pmcid: 6345198
Méndez R, Balanzá-Martínez V, Luperdi SC, Estrada I, Latorre A, González-Jiménez P, et al (2021) Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. J Intern Med 290(3):621–631. https://doi.org/10.1111/joim.13262
doi: 10.1111/joim.13262
pubmed: 33533521
pmcid: 8013333
Hosp JA, Dressing A, Blazhenets G, Bormann T, Rau A, Schwabenland M et al (2021) Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain 144:1263–1276
doi: 10.1093/brain/awab009
pubmed: 33822001
Almeria M, Cejudo JC, Sotoca J, Deus J, Krupinski J (2020) Cognitive profile following COVID-19 infection: clinical predictors leading to neuropsychological impairment. Brain, Behav Immun - Heal 9:100163
doi: 10.1016/j.bbih.2020.100163
Zhou H, Lu S, Chen J, Wei N, Wang D, Lyu H et al (2020) The landscape of cognitive function in recovered COVID-19 patients. J Psychiatr Res Elsevier Ltd 129:98–102
doi: 10.1016/j.jpsychires.2020.06.022
Potus F, Mai V, Lebret M, Malenfant S, Breton-Gagnon E, Lajoie AC et al (2020) Novel insights on the pulmonary vascular consequences of COVID-19. Am J Physiol - Lung Cell Mol Physiol 319:L277–L288
doi: 10.1152/ajplung.00195.2020
pubmed: 32551862
pmcid: 7414237
Ferrucci R, Dini M, Groppo E, Rosci C, Reitano MR, Bai F et al (2021) Long-lasting cognitive abnormalities after COVID-19. Brain Sci 11:1–11
doi: 10.3390/brainsci11020235
Chételat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S et al (2020) Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer’s disease and other dementias. Lancet Neurol England 19:951–962
doi: 10.1016/S1474-4422(20)30314-8
Blazhenets G, Schröter N, Bormann T, Thurow J, Wagner D, Frings L et al (2021) Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J Nucl Med 62:910–915
doi: 10.2967/jnumed.121.262128
pubmed: 33789937
pmcid: 8882885
Amato MP, Portaccio E, Goretti B, Zipoli V, Ricchiuti L, De Caro MF et al (2006) The Rao’s brief repeatable battery and stroop test: normative values with age, education and gender corrections in an Italian population. Mult Scler J Mult Scler 12:787–793
doi: 10.1177/1352458506070933
Arnarson PÖ, Ólason DP, Smári J, Sigurdsson JF (2009) The Beck depression inventory second edition (BDI-II): psychometric properties in Icelandic student and patient populations. Taylor & Francis 62:360–5
Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B et al (2022) EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. Eur J Nucl Med Mol Imaging 49:632–651
doi: 10.1007/s00259-021-05603-w
pubmed: 34882261
Nobili F, Arbizu J, Bouwman F, Drzezga A, Agosta F, Nestor P et al (2018) European association of nuclear medicine and european academy of neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol 25:1201–1217
doi: 10.1111/ene.13728
pubmed: 29932266
Eskian M, Alavi A, Khorasanizadeh MH, Viglianti BL, Jacobsson H, Barwick TD et al (2019) Effect of blood glucose level on standardized uptake value (SUV) in 18F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements. Eur J Nucl Med Mol Imaging 46:224–237
doi: 10.1007/s00259-018-4194-x
pubmed: 30350009
Lindström E, Oddstig J, Danfors T, Jögi J, Hansson O, Lubberink M (2020) Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases. NeuroImage Clin. Elsevier 28:102386
doi: 10.1016/j.nicl.2020.102386
Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH et al (2016) SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med. United States. 57:1316–22
doi: 10.2967/jnumed.116.174615
Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN et al (2017) Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer’s disease. Assess Dis Monit 9:25–34
Fontana IC, Bongarzone S, Gee A, Souza DO, Zimmer ER (2020) PET imaging as a tool for assessing COVID-19 brain changes. Trends Neurosci 43:935–938
doi: 10.1016/j.tins.2020.10.010
pubmed: 33131922
pmcid: 7580682
Duan K, Premi E, Pilotto A, Cristillo V, Benussi A, Libri I et al (2021) Alterations of frontal-temporal gray matter volume associate with clinical measures of older adults with COVID-19. Neurobiol Stress 14:100326
doi: 10.1016/j.ynstr.2021.100326
pubmed: 33869679
pmcid: 8041745
Huang Y, Ling Q, Manyande A, Wu D, Xiang B (2022) Brain imaging changes in patients recovered from COVID-19: a narrative review. Front Neurosci 16:855868
doi: 10.3389/fnins.2022.855868
pubmed: 35527821
pmcid: 9072792
Rudroff T, Workman CD, Ponto LLB (2021)
doi: 10.3390/v13112283
pubmed: 34835088
pmcid: 8625263
Dressing A, Bormann T, Blazhenets G, Schroeter N, Walter LI, Thurow J et al (2022) Neuropsychologic profiles and cerebral glucose metabolism in neurocognitive long COVID syndrome.". J Nucl Med 63:1058–1063
doi: 10.2967/jnumed.121.262677
pubmed: 34649946
pmcid: 9258569
Vélez M, Falconí Paez A, Nicolalde B, Esquetini-Vernon C, Lara-Taranchenko Y, Zambrano K et al (2022) Cognitive impairment or dementia in post-acute COVID-19 syndrome. Two suspects and a perfect detective: positron emission tomography (PET) scan. Eur Neuropsychopharmacol 61:91–93
doi: 10.1016/j.euroneuro.2022.06.010
pubmed: 35870344
pmcid: 9259455
Danics K, Forrest SL, Kapas I, Erber I, Schmid S, Törő K et al (2021) Neurodegenerative proteinopathies associated with neuroinfections. J Neural Transm 128:1551–1566
doi: 10.1007/s00702-021-02371-7
pubmed: 34223998
Fulop T, Witkowski JM, Larbi A, Khalil A, Herbein G, Frost EH (2019) Does HIV infection contribute to increased beta-amyloid synthesis and plaque formation leading to neurodegeneration and Alzheimer’s disease? J Neurovirol United States 25:634–647
doi: 10.1007/s13365-019-00732-3
Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P et al (2022) SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 604:697–707
doi: 10.1038/s41586-022-04569-5
pubmed: 35255491
pmcid: 9046077
Ciaccio M, Lo Sasso B, Scazzone C, Gambino CM, Ciaccio AM, Bivona G et al (2021) COVID-19 and Alzheimer’s disease. Brain Sci 11:1–10
doi: 10.3390/brainsci11030305
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM et al (2000) Inflammation and Alzheimer’s disease. Neurobiol Aging 21:383–421
doi: 10.1016/S0197-4580(00)00124-X
pubmed: 10858586
pmcid: 3887148
Webers A, Heneka MT, Gleeson PA (2020) The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer’s disease. Immunol Cell Biol United States 98:28–41
doi: 10.1111/imcb.12301
Chouhan JK, Püntener U, Booth SG, Teeling JL (2021) Systemic inflammation accelerates changes in microglial and synaptic markers in an experimental model of chronic neurodegeneration. Front Neurosci 15:760721
doi: 10.3389/fnins.2021.760721
pubmed: 35058740
Darif D, Hammi I, Kihel A, El Idrissi SI, Guessous F, Akarid K (2021) The pro-inflammatory cytokines in COVID-19 pathogenesis: what goes wrong? Microb Pathog 153:104799
doi: 10.1016/j.micpath.2021.104799
pubmed: 33609650
pmcid: 7889464
Rau A, Schroeter N, Blazhenets G, Dressing A, Walter LI, Kellner E et al (2022) Widespread white matter oedema in subacute COVID-19 patients with neurological symptoms. Oxford University Press (OUP), Brain
doi: 10.1093/brain/awac045
Qin Y, Wu J, Chen T, Li J, Zhang G, Wu D, et al (2021) Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. J Clin Invest 131
Murphy MP, LeVine H 3rd (2010) Alzheimer’s disease and the amyloid-beta peptide. J Alzheimers Dis 19:311–323
doi: 10.3233/JAD-2010-1221
pubmed: 20061647
pmcid: 2813509